

Table of Contents

Introduction **xi**

Case 1:

Patient Blood Management Considerations in an Orthopedic Surgery Patient **1**

Stephen Walsh, MD

Objectives 1
Case Scenario 1
How Should This Patient’s Anemia Be Managed? 2
Is There a Role for ESAs in the Management of This Patient? 4
Should the Presence of Diabetes Influence the Management of This Patient? 5
What Intraoperative Strategies Should Be Considered? 5
Is There a Role for Preoperative Autologous Donation Before Elective Joint Replacement Surgery? 6
How Should the Patient Be Managed in the Postoperative Period? 6
What Is the Expected Rate of Transfusion in Uncomplicated Primary Elective Hip Replacement Using Patient Blood Management Treatment Strategies? 8
Key Learning Points 8
References 9

Case 2:

Patient Blood Management in a Cardiovascular Surgery Patient **11**

Tonya de Waal, MD, and Marianne de Bretan-Berg, RN, CFRN

Objectives 11
Case Scenario 11
What Concerns Are Raised About This Patient Anticipating Hip Arthroplasty? 12
What Is the Prevalence of Anemia in Cardiac Surgery? 12
What Are the Risks Associated with Preoperative Anemia? 13
What Is the Likelihood of Transfusion and What Is the “Downside” of Transfusion in This Setting? 13
What Preoperative Assessment Should Be Performed? 13
What Additional Laboratory Tests Should Be Ordered for This Patient? 14
Should the TRUST Score Affect the Management of This Patient? 15

Should ESAs Be Given? 15
What Operative Strategies Should Be Considered? 16
Key Learning Points. 19
References 19

**Case 3:
Management of an Anemic Obstetric Patient 21**

Jed B. Gorlin, MD, MBA, and Evelyn L. Lockhart, MD

Objectives 21
Case Scenario 21
Anemia in Pregnancy 22
Does Oral Iron Help in Pregnancy? 23
Obstetric Hemorrhage: Definition, Epidemiology, and Risk Factors 24
After the Hemorrhage Is Controlled 36
Key Learning Points. 36
References 37

**Case 4:
Management of a Gynecologic Oncology Patient Requiring Surgery 41**

Nimesh P. Nagarsheth, MD

Objectives. 41
Case Scenario 41
Case Discussion 41
What Preoperative Care Measures Should Be Undertaken? 42
What Are the Surgical Approach Considerations? 43
Does Use of an ESA in a Patient with Cancer and a Hemoglobin
Level of 9.2 g/dL Pose Any Concern? 44
Does Transfusion Pose a Particular Risk for Patients with
Malignancy? 45
What Are the Intraoperative Considerations? 46
What Are the Components of Postoperative Care That Should Be
Considered? 47
Key Learning Points. 48
References 48

**Case 5:
Patient Blood Management in a Hematology/Oncology Patient 51**

Patricia A. Ford, MD, and Vasundhara Singh, MD

Objectives. 51
Case Scenario 51
What Are the Main Concerns for Initial Hematologic Management
for This Patient? 52

What Is the Incidence of Anemia in Cancer? 52

What Are the Benefits and Risks of Transfusion? 52

What Is the Appropriate Red Cell Transfusion Threshold for
This Patient? 53

Restrictive vs Liberal Transfusion Therapy 53

What Other Strategies Should Be Considered When Managing
This Patient? 54

What Medical Strategies Can Be Used to Manage This Patient’s
Anemia Once the Bleeding Is Controlled? 55

What Is an Appropriate Prophylactic Platelet Transfusion Threshold
in This Patient? 57

What Treatment Is Recommended if the Patient Were to Develop
Worsening Hemoptysis and Potential for Pulmonary Hemorrhage? . . 58

Therapies of Consideration 59

Key Learning Points 60

References 60

Case 6:
Management of a Jehovah’s Witness Patient 63

Margit Kaufman, MD, and Sherri Ozawa, RN

Objectives 63

Case Scenario 63

What Is the Basis for the Belief System to Which Jehovah’s Witness
Patients Ascribe Their View on Blood Component Transfusion? 64

What Are the Principles of Patient Self-Determination and
Autonomy? How Can This Patient Make Informed Decisions
Regarding His Care? 64

What Types of Conversations and Discussions Should Take Place
with a Jehovah’s Witness Patient in Both Elective and Emergent
Situations? Are There Resources to Help the Patient and the
Health-Care Provider Caring for a Jehovah’s Witness? 66

What Type of Additional Documentation of the Patient’s Preferences
Should Be Completed by Caregivers? Are There Specific Concerns
with an Incapacitated Adult Patient? 68

What Initial Steps Can the Provider Take to Stabilize the Patient?
How Can the Health-Care Provider Physiologically Optimize the
Patient to Tolerate Severe Anemia? 68

What Are the Next Steps in the Patient’s Care Now That There Is
No Active Bleeding, but the Patient Is Still Intubated with Altered
Mental Status? 70

The Patient Is Having Some Occasional Episodes of Hypotension
with Mean Arterial Pressures Between 55 and 60 mmHg. What
Management Options Are Appropriate? 70

What Additional Steps in the Management of the Severely Anemic Jehovah's Witness Patient Can the ICU Team Initiate? 71

What Are Hemoglobin-Based Oxygen Carriers and Would They Be Indicated in This Case? 72

What Additional Steps Can the ICU Team Take to Optimize Recovery of the Patient? 73

What Additional Risks Does This Patient Face During His Recovery? . . . 75

Although Phlebotomy and Laboratory Tests Are Part of Routine Care of Critically Ill Patients, What Options Are There to Prevent Additional Anemia Caused by Excessive Laboratory Work? 75

Key Learning Points. 76

References 77

Case 7:
Management of Bleeding in the Setting of Target-Specific Oral Anticoagulants 79

Yulia Lin, MD, FRCPC, and Katerina Pavenski, MD, FRCPC

Objectives. 79

Case Scenario 80

What Is the Mechanism of Action of TSOACs? 80

What Are the Indications for TSOACs? 80

What Is the Risk of Bleeding with TSOACs Compared with Warfarin? . . 81

What Factors Increase the Risk of Bleeding with TSOACs? 82

What Coagulation Testing Can Be Performed to Help with the Management of This Patient? 84

What General Measures Should Be Employed for This Bleeding Patient? 85

In the Setting of Severe or Life-Threatening Bleeding, What Reversal Strategies Can Be Considered for This Patient? 87

Key Learning Points. 88

References 88

Case 8:
Management of Bleeding in the Setting of Antiplatelet Drugs 91

Katerina Pavenski, MD, FRCPC, and Yulia Lin, MD, FRCPC

Objectives. 91

Case Scenario 91

Immediate Patient Management 92

What Laboratory Investigations May Help Guide Further Management of This Patient? 92

What Is the Patient's Hemostatic Defect? 93

What Is the Mechanism of Action of Aspirin, Clopidogrel, and Eptifibatid? How Long Do the Effects of These Drugs Persist After Their Administration? 93

What Is the Most Appropriate Management of the Patient’s Hemostatic Defect? 94

What Are the Risks of a Platelet Transfusion? Are There Alternative Approaches That Might Be Useful for This Patient? 95

What Are the Alternatives to Platelet Transfusion in This Context? 96

What Patient Blood Management Strategies Could Be Used to Improve Tolerance of Anemia? 97

What Should the Red Blood Cell Transfusion Threshold Be for This Patient? 98

Key Learning Points 98

References 98

**Case 9:
Strategies for Warfarin Reversal in the Hemorrhaging Patient 101**

Joseph Sweeney, MD, FACP, FRCPath

Objectives 101

Case Scenario 101

What Are the Main Concerns Regarding This Patient Upon Presentation? 101

What Is the Bleeding Risk of Endoscopy in Patients Taking Warfarin? 102

What Is the Mechanism of Action of Warfarin? 103

How Can Reversal of Warfarin Be Achieved? 103

What Other Aspects of Clinical Management Need to Be Considered Regarding This Patient? 108

Is There a Risk of Thrombosis After Warfarin Reversal? 109

How Urgently Should the Endoscopy Be Performed? 109

Key Learning Points 110

References 110

**Case 10:
Management of Anemia in a Critically Ill Patient 113**

Howard L. Corwin, MD, FCCM

Objectives 113

Case Scenario 113

Are There Aspects of Anemia Particular to Critically Ill Patients? 114

What Is the Role of Erythropoietin in the Critically Ill Patient? 115

What Laboratory Abnormalities Are to Be Expected? 115

Is There a Role for Red Blood Cell Transfusion in Critically Ill Patients? 116

What Are the Risks and Benefits of Transfusion in Critically Ill Patients? 117

What Alternatives to RBC Transfusion Should Be Considered? 118

How Have RBC Transfusion Practices in Critical Care Patients Changed Since Publication of the TRICC Trial? 119

Key Learning Points. 120

References 120

Appendix 1 123

Appendix 2 125

Index. 127